Abstract PO1-18-05: Combination Treatment with CDK2 Inhibitor (BLU-222) and Either Palbociclib or Ribociclib is Synergistic in Pre-Clinical Models of CDK4/6 Inhibitor-Resistant Breast Cancer
Cancer Research（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined